Learning whether to subtract beta-blockers: it's about time

Sean van Diepen; Paul W Armstrong

doi:10.1093/eurheartj/ehaa1033

Learning whether to subtract beta-blockers: it's about time

Eur Heart J. 2021 Mar 1;42(9):915-918. doi: 10.1093/eurheartj/ehaa1033.

Authors

Sean van Diepen^{1

2

3}, Paul W Armstrong^{1

2}

Affiliations

¹ Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
² Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada.
³ Department of Critical Care Medicine, University of Alberta, Edmonton, Canada.

PMID: 33428708
DOI: 10.1093/eurheartj/ehaa1033

Abstract

Proposed framework for foundational and provisional secondary prevention therapy over time in low-risk post-MI patients. Foundational therapies should be considered in all patients without contraindications, while provisional therapies should be considered in selected patients with comorbidities or post-infarction complications. The horizontal time axis proposes duration of therapies and timeframes for pharmacotherapeutic re-assessment, and should be responsive to the temporal evolution of post-MI risk and events. ADP, adenosine diphosphate receptor inhibitors; ASA, acetylsalicylic acid; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; RAAS, renin-angiotensin-aldosterone system; RCT, randomized controlled trials; TG, triglyceride. *Pending guideline recommendations.

Publication types

Editorial
Comment

MeSH terms

Angiotensin-Converting Enzyme Inhibitors
Cohort Studies
Denmark
Heart Failure*
Humans
Hypertension* / drug therapy
Myocardial Infarction* / drug therapy
Renin-Angiotensin System
Reperfusion

Substances

Angiotensin-Converting Enzyme Inhibitors